Literature DB >> 3081686

Characterization of sodium-dependent [3H]GBR-12935 binding in brain: a radioligand for selective labelling of the dopamine transport complex.

A Janowsky, P Berger, F Vocci, R Labarca, P Skolnick, S M Paul.   

Abstract

High-affinity and saturable binding sites for the diphenyl-substituted piperazine derivative [3H]GBR-12935 have been characterized in crude synaptosomal membranes prepared from rat brain. The specific binding of [3H]GBR-12935 is sodium-dependent and is unevenly distributed among various brain regions, with the highest concentration of binding sites being found in the corpus striatum and nucleus accumbens. Sodium-dependent [3H]GBR-12935 binding in all other brain areas was 10% or less of the binding found in the striatum. The affinity of [3H]GBR-12935 for binding sites in the striatum is increased in the presence of Na+ but other cations, including K+, Ca2+, or Mg2+, inhibit specific binding. There is an excellent correlation (r = 0.96, p less than 0.01) between the potencies of a series of drugs in inhibiting [3H]GBR-12935 binding to striatal membranes and their potencies in inhibiting [3H]3,4-dihydroxyphenylethylamine ([3H]dopamine) uptake in synaptosomes. Agonists and antagonists of other neurotransmitter receptor or drug recognition sites have little or no effect on specific [3H]GBR-12935 binding to striatal membranes. In addition, prior intracerebroventricular administration of 6-hydroxydopamine results in a decrease in the number of specific [3H]GBR-12935 binding sites in the striatum. These data indicate that [3H]GBR-12935 is a selective radioligand of the presynaptic dopamine transport complex in brain.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081686     DOI: 10.1111/j.1471-4159.1986.tb00649.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  19 in total

1.  Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation.

Authors:  K A Neve; R L Neve; S Fidel; A Janowsky; G A Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

3.  Neuropharmacological characterization of local ibogaine effects on dopamine release.

Authors:  M S Reid; K Hsu; K H Souza; P A Broderick; S P Berger
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Characterization of the human dopamine transporter heterologously expressed in BHK-21 cells.

Authors:  T Lenhard; K Marheineke; B Lingen; W Haase; R Hammermann; H Michel; H Reiländer
Journal:  Cell Mol Neurobiol       Date:  1998-06       Impact factor: 5.046

5.  The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Authors:  Barbara J Caldarone; Neil E Paterson; Jia Zhou; Daniela Brunner; Alan P Kozikowski; Koen G C Westphal; Gerdien A H Korte-Bouws; Jolanda Prins; S Mechiel Korte; Berend Olivier; Afshin Ghavami
Journal:  J Pharmacol Exp Ther       Date:  2010-09-23       Impact factor: 4.030

6.  Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains.

Authors:  C M Dersch; H C Akunne; J S Partilla; G U Char; B R de Costa; K C Rice; F I Carroll; R B Rothman
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

7.  The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Authors:  Dieter Scheller; Christoph Ullmer; Reinhard Berkels; Mirella Gwarek; Hermann Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-14       Impact factor: 3.000

8.  Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.

Authors:  Jakob A Shimshoni; Ilan Winkler; Ezekiel Golan; David Nutt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-20       Impact factor: 3.000

9.  Stereoselective behavioral effects of Lu 19-005 in monkeys: relation to binding at cocaine recognition sites.

Authors:  S Rosenzweig-Lipson; J Bergman; R D Spealman; B K Madras
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  MPTP lesions of the nigrostriatal dopaminergic projection decrease [3H]1-[1-(2-thienyl)cyclohexyl]piperidine binding to PCP site 2: further evidence that PCP site 2 is associated with the biogenic amine reuptake complex.

Authors:  H C Akunne; J N Johannessen; B R de Costa; K C Rice; R B Rothman
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.